ReviewExpert review of anti-infective therapy2016
Helicobacter pylori therapy: a paradigm shift.
Review in Expert review of anti-infective therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the Advantages Over Conventional Therapies for Eradication ofInfection and drug resistance · 2023Trial
- Review
- Effect of a WeChat-based medication reminder platform onFrontiers in medicine · 2026Article
- Global Profile of Drug Resistance Related toHealth science reports · 2025Review
- The Cost-Effectiveness of Adding Helicobacter Pylori Screening to the National Gastric Cancer Screening Program in Korea: Protocol for a Cost-Effectiveness Modeling Study.JMIR research protocols · 2025Article
- Yeast Complementation Assays Demonstrating the Importance of the Affinity Tag Position in Membrane Protein Purification, as Exemplified bySmall science · 2025Article
- The efficacy and safety of Vonoprazan and Tegoprazan inTherapeutic advances in gastroenterology · 2025Article
- High-dose amoxicillin and pantoprazole regimen forPrzeglad gastroenterologiczny · 2025Article
- Experience of Metronidazole Triple Therapy After Clarithromycin Triple Therapy Failure forJournal of clinical medicine · 2024Article
- Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics.Drug delivery · 2024Review
- The Aging Stomach: Clinical Implications ofInternational journal of molecular sciences · 2024Review
- Article
- Treatment ofHealth science reports · 2023Article
- Article
- From Antibiotic Resistance to Antibiotic Renaissance: A New Era in Helicobacter pylori Treatment.Cureus · 2023Review
- Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management.United European gastroenterology journal · 2023Article
- Focusing onFrontiers in cellular and infection microbiology · 2023Review
- Multidrug resistance inFrontiers in microbiology · 2023Review
- How widespread and convenientExpert review of gastroenterology & hepatology · 2023Review
- Comparative effectiveness of different probiotics supplements for triple helicobacter pylori eradication: a network meta-analysis.Frontiers in cellular and infection microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Helicobacter pylori (H. Pylori) is a leading cause of gastroduodenal disease, including gastric cancer. H. pylori eradication therapies and their efficacy are summarized. A number of current treatment regimens will reliably yield >90% or 95% cure rates with susceptible strains. None has proven to be superior. We show how to predict the efficacy of a regimen in any population provided one knows the prevalence of antibiotic resistance. As with other infectious diseases, therapy should always be susceptibility-based. Susceptibility testing should be demanded. We provide recommendations for empiric therapies when that is the only option and describe how to distinguish studies providing misinformation from those providing reliable and interpretable data. When treated as an infectious disease, high H. pylori cure rates are relatively simple to reliably achieve.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.